View Item 

Show simple item record

Treatment of gastroparesis: a multidisciplinary clinical review

dc.contributor.authorAbell, Thomas L.en_US
dc.contributor.authorBernstein, Vr. K.en_US
dc.contributor.authorCutts, T.en_US
dc.contributor.authorFarrugia, G.en_US
dc.contributor.authorForster, J.en_US
dc.contributor.authorHasler, William L.en_US
dc.contributor.authorMcCallum, Richard W.en_US
dc.contributor.authorOlden, Kevinen_US
dc.contributor.authorParkman, Henry P.en_US
dc.contributor.authorParrish, C. R.en_US
dc.contributor.authorPasricha, P. J.en_US
dc.contributor.authorPrather, Charlene M.en_US
dc.contributor.authorSoffer, E. E.en_US
dc.contributor.authorTwillman, R.en_US
dc.contributor.authorVinik, Aaron I.en_US
dc.date.accessioned2010-06-01T22:37:05Z
dc.date.available2010-06-01T22:37:05Z
dc.date.issued2006-04en_US
dc.identifier.citationabell , t. l. ; bernstein , vr. k. ; cutts , t. ; farrugia , g. ; forster , j. ; hasler , w. l. ; mccallum , r. w. ; olden , k. w. ; parkman , h. p. ; parrish , c. r. ; pasricha , p. j. ; prather , c. m. ; soffer , e. e. ; twillman , r. ; vinik , a. i. (2006). "Treatment of gastroparesis: a multidisciplinary clinical review." Neurogastroenterology & Motility 18(4): 263-283. <http://hdl.handle.net/2027.42/75594>en_US
dc.identifier.issn1350-1925en_US
dc.identifier.issn1365-2982en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75594
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16553582&dopt=citationen_US
dc.format.extent178728 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 The Authors Journal compilation 2006 Blackwell Publishing Ltden_US
dc.subject.otherGastroparesisen_US
dc.subject.otherGastric Emptyingen_US
dc.subject.otherProkinetic Agentsen_US
dc.subject.otherAntiemetic Agentsen_US
dc.subject.otherBotulinum Toxinen_US
dc.titleTreatment of gastroparesis: a multidisciplinary clinical reviewen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum** University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* University of Mississippi Medical Center, Jackson, MS, USAen_US
dc.contributor.affiliationother† Diabetes Center, Mamaroneck, NY, USAen_US
dc.contributor.affiliationother† University of Tennessee Health Science Center, Memphis, TN, USAen_US
dc.contributor.affiliationother§ Mayo Clinic College of Medicine, Rochester, MN, USAen_US
dc.contributor.affiliationother¶ University of Kansas Medical Center, Kansas City, KS, USAen_US
dc.contributor.affiliationother†† University of South Alabama, Mobile, AL, USAen_US
dc.contributor.affiliationother†† Temple University School of Medicine, Philadelphia, PA, USAen_US
dc.contributor.affiliationother§§ University of Virginia Health System, Charlottesville, VA, USAen_US
dc.contributor.affiliationother¶¶ University of Texas Medical Branch, Galveston, TX, USAen_US
dc.contributor.affiliationother*** Saint Louis University, St Louis, MO, USAen_US
dc.contributor.affiliationother††† Cedars-Sinai Medical Center, Los Angeles, CA, USAen_US
dc.contributor.affiliationother††† Eastern Virginia Medical School, Norfolk, VA, USAen_US
dc.identifier.pmid16553582en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75594/1/j.1365-2982.2006.00760.x.pdf
dc.identifier.doi10.1111/j.1365-2982.2006.00760.xen_US
dc.identifier.sourceNeurogastroenterology & Motilityen_US
dc.identifier.citedreferenceParkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592 – 622.en_US
dc.identifier.citedreferenceSoykan I, Sivri B, Sarosiek I, Kierran B, McCallum RW. Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398 – 404.en_US
dc.identifier.citedreferenceRevicki DA, Rentz AM, Dubois D et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 2004; 13: 833 – 44.en_US
dc.identifier.citedreferenceFarup CE, Williams GR, Leidy NK, Helbers L, Murray M, Quigley EMM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998; 21: 1699 – 706.en_US
dc.identifier.citedreferenceHoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94: 1029 – 33.en_US
dc.identifier.citedreferenceTalley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756 – 80.en_US
dc.identifier.citedreferenceHorowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol 1986; 1: 97 – 113.en_US
dc.identifier.citedreferenceJones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24: 1264 – 9.en_US
dc.identifier.citedreferenceStanghellini V, Tosetti C, Paternico A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 1036 – 42.en_US
dc.identifier.citedreferenceSarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783 – 8.en_US
dc.identifier.citedreferenceDelgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meals size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127: 1685 – 94.en_US
dc.identifier.citedreferenceMearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90: 1919 – 25.en_US
dc.identifier.citedreferenceCamilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 94 – 9.en_US
dc.identifier.citedreferenceKaramanolis G, Arts J, Caenepeel P, Verbeke K, Janssens J, Tack J. Determinants of symptom pattern in idiopathic gastroparesis: gastric emptying or proximal stomach dysfunction. Gastroenterology 2005; 128: A547 (abstract).en_US
dc.identifier.citedreferenceSamsom M, Salet GAM, Roelofs JMM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ. Compliance of the proximal stomach and dyspeptic symptoms in patients with type 1 diabetes mellitus. Dig Dis Sci 1995; 40: 2037 – 42.en_US
dc.identifier.citedreferenceBredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 264 – 72.en_US
dc.identifier.citedreferenceRevicki DA, Rentz AM, Dubois D et al. Development and validation of a patient-assessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003; 18: 141 – 50.en_US
dc.identifier.citedreferenceParrish CR, Yoshida C. Nutrition intervention for the patient with gastroparesis: an update. Pract Gastroenterol 2005; 29: 29 – 35.en_US
dc.identifier.citedreferenceEmerson AP. Foods high in fiber and phytobezoar formation. J Am Diet Assoc 1987; 87: 1675 – 7.en_US
dc.identifier.citedreferenceSturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60: 422 – 7.en_US
dc.identifier.citedreferenceMcCallum TW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983; 6: 463 – 7.en_US
dc.identifier.citedreferenceRicci D, Saltzman M, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985; 7: 25 – 32.en_US
dc.identifier.citedreferenceSnape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med 1982; 96: 444 – 6.en_US
dc.identifier.citedreferenceChen JDZ, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis 1995; 13: 275 – 90.en_US
dc.identifier.citedreferenceMcCallum RW, Valenzuela G, Polepalle S. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258: 136 – 42.en_US
dc.identifier.citedreferenceGanzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153: 1469 – 75.en_US
dc.identifier.citedreferenceShaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc 2004; 44: 661 – 5.en_US
dc.identifier.citedreferencePatterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230 – 4.en_US
dc.identifier.citedreferenceSilvers D, Kipnes M, Broadstone V et al. Domperidone in the management of symptoms of diabetic gastroparesis; efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clin Ther 1998; 20: 438 – 53.en_US
dc.identifier.citedreferenceKoch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989; 84: 1069 – 75.en_US
dc.identifier.citedreferenceSoykan I, Lin Z, Jones S, Chen J, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 952 – 7.en_US
dc.identifier.citedreferenceSawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India 2004; 52: 626 – 8.en_US
dc.identifier.citedreferenceBasque J-R, Noritake M, Mizogami H, Katsura Y. Efficacy of itopride hydrochloride on gastric emptying in patients with diabetic gastroparesis. Gastroenterology 2005; 128: A156 (abstract).en_US
dc.identifier.citedreferenceFarrugia G, Macielaq M, Peeters TL, Sarr MG, Galdes A, Szurszewski JH. Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle. Am J Physiol 1997; 36: G404 – 12.en_US
dc.identifier.citedreferenceWeber FH, Richard RE, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485 – 90.en_US
dc.identifier.citedreferenceMoshiree B, Gupta V, Verne GN, Toskes PP. Azithromycin: a new therapy for gastroparesis. Gastroenterology 2005; 128: A547 (abstract).en_US
dc.identifier.citedreferenceKendall BJ, Chakravarti A, Kendall E, Soykan L, McCallum RW. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy antrectomy gastroparesis. Aliment Pharmacol Ther 1997; 11: 381 – 5.en_US
dc.identifier.citedreferenceParkman HP, Pagano AP, Vozzelli M, Ryan JP. The gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in the rabbit stomach. Am J Physiol 1995; 269: G418 – 26.en_US
dc.identifier.citedreferenceParkman HP, Pagano AP, Ryan JP. Erythromycin inhibits pyloric muscle by releasing nitric oxide and VIP through neuronal motilin receptors. Gastroenterology 1996; 111: 682 – 90.en_US
dc.identifier.citedreferenceCoulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998; 43: 395 – 400.en_US
dc.identifier.citedreferenceMaganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98: 259 – 63.en_US
dc.identifier.citedreferenceRichards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88: 203 – 7.en_US
dc.identifier.citedreferenceRay WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089 – 96.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Snape W et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying. A randomized double-blind placebo controlled trial. Aliment Pharmacol Ther 2000; 14: 1653 – 6.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Geenen DJ et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double-blind, placebo controlled trial. Gut 2001; 49: 395 – 401.en_US
dc.identifier.citedreferenceMcCallum RW, Rogel R, Fang JC, Altman RS, Faichney JD, Goldstein BJ. Mitemacil fumarate (GM-611) provided symptomatic relief of diabetic gastroparesis, especially in type I diabetics: results of a 12-week, multi-center, double-blind, placebo-controlled, randomized phase 2b study. Gastroenterology 2005; 128: A467 (abstract).en_US
dc.identifier.citedreferenceMurray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut 2005; 54: 1693 – 8.en_US
dc.identifier.citedreferenceTack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22: 847 – 53.en_US
dc.identifier.citedreferenceFraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride. Gut 1994; 35: 172 – 8.en_US
dc.identifier.citedreferenceBraden B, Enghofer M, Schaub M, Usadel KH, Caspary WJ, Lembcke B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002; 16: 1341 – 6.en_US
dc.identifier.citedreferenceAbell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616 – 20.en_US
dc.identifier.citedreferenceJones MP. Access options for withdrawn motility-modifying agents. Am J Gastroenterol 2002; 97: 2184 – 8.en_US
dc.identifier.citedreferencePrather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463 – 8.en_US
dc.identifier.citedreferenceDegen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745 – 51.en_US
dc.identifier.citedreferenceTougas G, Chen Y, Luo D, Salter J, D'Elia T, Earnest DL. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003; 124: A54 (abstract).en_US
dc.identifier.citedreferenceMorganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 2321 – 7.en_US
dc.identifier.citedreferenceKanaizumi T, Nakano H, Matsui Y et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 335 – 7.en_US
dc.identifier.citedreferenceAsakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61: 175 – 82.en_US
dc.identifier.citedreferencePotet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 1007 – 12.en_US
dc.identifier.citedreferenceMalagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980; 78: 286 – 93.en_US
dc.identifier.citedreferenceMcCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology 1983; 84: 1573 – 7.en_US
dc.identifier.citedreferenceParkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut 1999; 45: 346 – 54.en_US
dc.identifier.citedreferenceKishibayashi N, Karasawa A. Effects of KW-5092 on antroduodenal coordination and gastric emptying in guinea pigs. J Pharm Pharmacol 1998; 50: 1045 – 50.en_US
dc.identifier.citedreferenceUeki S, Seiki M, Yoneta T et al. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther 1003; 264: 152 – 7.en_US
dc.identifier.citedreferenceMcCallum R, Zarling E, Goetsch CA et al. Nizatidine controlled release has gastric prokinetic effects in patients with gastroesophageal reflux disease (GERD). Gastroenterology 2004; 126 ( Suppl. 2 ): A-335.en_US
dc.identifier.citedreferenceRosa-e-Silva L, Troncon LE, Oliveira RB, Iazigi N, Gallo L Jr, Foss MC. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995; 9: 179 – 83.en_US
dc.identifier.citedreferenceHuilgol V, Evans J, Hellman RS, Soergel KH. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls. Aliment Pharmacol Ther 2002; 16: 945 – 50.en_US
dc.identifier.citedreferenceLossos IS, Mevorach D, Oren R. Thiethylperazine treatment of gastroparesis diabeticorum. Ann Pharmacother 1992; 26: 1016.en_US
dc.identifier.citedreferenceKranke P, Morin AM, Roewer N et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2002; 95: 133 – 43.en_US
dc.identifier.citedreferenceHurwitz A, Robinson RG, Herrin WF, Christie J. Oral anticholinergics and gastric emptying. Clin Pharmacol Ther 1982; 31: 168 – 74.en_US
dc.identifier.citedreferenceJaup BH, Dotevall G. The effect of pirenzipine and L-hyoscyamine on gastric emptying and salivary secretion in healthy volunteers. Scand J Gastroenterol 1981; 16: 769 – 73.en_US
dc.identifier.citedreferenceKranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002; 46: 238 – 44.en_US
dc.identifier.citedreferenceKothari SN, Boyd WC, Bottcher ML, Lambert PJ. Antiemetic efficacy of prophylactic dimenhydrinate vs. ondansetron: a randomized, prospective trial in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2000; 14: 926 – 9.en_US
dc.identifier.citedreferenceStewart JJ, Wood MJ, Wood CD, Mims ME. Effects of motion sickness and antimotion sickness drugs on gastric function. J Clin Pharmacol 1994; 34: 635 – 43.en_US
dc.identifier.citedreferenceEl-Gammal A, Rashed HM, Taylor J, Werkman R, Abell TL. Long term ondansetron therapy is beneficial in patients with chronic nausea and vomiting. Gastroenterology 2000; 118: A1170 (abstract).en_US
dc.identifier.citedreferenceNetzer P, Gaia C, Lourens ST et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers ? Aliment Pharmacol Ther 2002; 16: 119 – 27.en_US
dc.identifier.citedreferenceNielsen OH, Hvid-Jacobsen K, Lund P, Langoholz E. Gastric emptying and subjective symptoms of nausea: lack of effect of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46: 89 – 96.en_US
dc.identifier.citedreferenceStacher G, Bergmann H, Schneider C et al. Effects of the 5-HT 3 receptor antagonist ICS 205–930 on fat-delayed gastric emptying and antral motor activity. Br J Clin Pharmacol 1990; 30: 41 – 8.en_US
dc.identifier.citedreferenceMcCallum RW, Soykan I, Sridhar KR et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 77 – 80.en_US
dc.identifier.citedreferenceAdelhoj B, Petring OU, Brynnum J et al. Effect of diazepam on drug absorption and gastric emptying in man. Br J Anaesth 1985; 57: 1107 – 9.en_US
dc.identifier.citedreferenceDando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777 – 94.en_US
dc.identifier.citedreferenceDiemunsch P, Schoeffler P, Bryssine B et al. Antiemetic activity of the NK 1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999; 82: 274 – 6.en_US
dc.identifier.citedreferencePrakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998; 43: 1951 – 6.en_US
dc.identifier.citedreferenceSawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for persistent or recurrent vomiting in diabetic patients. Gastroenterology 2001; 120: A243 (abstract).en_US
dc.identifier.citedreferenceGupta YK, Sharma M. Reversal of pyrogallol-induced delay in gastric emptying in rats by ginger ( Zingiber officinale ). Methods Find Exp Clin Pharmacol 2001; 23: 501 – 3.en_US
dc.identifier.citedreferenceGonlachanvit S, Chen YH, Hasler WL et al. Ginger reduces hyperglycemia-evoked gastric dysrhythmias in healthy humans: possible role of endogenous prostaglandins. J Pharmacol Exp Ther 2003; 307: 1098 – 103.en_US
dc.identifier.citedreferenceRoscoe JA, Morrow GR, Hickok JT et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 2003; 26: 731 – 42.en_US
dc.identifier.citedreferenceWang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med 2004; 24: 163 – 5.en_US
dc.identifier.citedreferenceRathmann W, Enck P, Frieling T, Gries FA. Visceral afferent neuropathy in diabetic gastroparesis. Diabetes Care 1991; 14: 1086 – 9.en_US
dc.identifier.citedreferenceHasler WL, Soudah HC, Dulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108: 727 – 36.en_US
dc.identifier.citedreferencePimentel M, Sam C, Lin HC. Indomethacin improves symptoms and electrogastrographic findings in patients with gastric dysrhythmias. Neurogastroenterol Motil 2001; 13: 422 (abstract).en_US
dc.identifier.citedreferenceSimonian HP, Parkman HP. Effect of prostaglandin inhibition with ketorolac on gastric activity and dyspeptic symptoms in patients with dyspeptic symptoms. Am J Gastroenterol 2003; 98 ( Suppl. ): S58.en_US
dc.identifier.citedreferenceGorelick AB, Koshy SS, Hooper FG et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 2756: G460 – 6.en_US
dc.identifier.citedreferenceGoldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109 – 18.en_US
dc.identifier.citedreferenceChial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003; 284: G130 – 7.en_US
dc.identifier.citedreferenceGorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994; 35: 496 – 500.en_US
dc.identifier.citedreferenceDuby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 160 – 73.en_US
dc.identifier.citedreferenceCarroll DG, Kline KM, Malnar KF. Role of topiramate for the treatment of painful diabetic peripheral neuropathy. Pharmacotherapy 2004; 24: 1186 – 93.en_US
dc.identifier.citedreferenceMalcom A, Camilleri M, Kost L et al. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmcol Ther 2000; 14: 783 – 93.en_US
dc.identifier.citedreferenceMaurer AH, Krevsky B, Knight LC, Brown K. Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med 1996; 37: 818 – 22.en_US
dc.identifier.citedreferenceMercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898 – 904.en_US
dc.identifier.citedreferenceTawfik MO, Bryuzgin V, Kourteva G, FEN-INT-20 Study Group. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 2004; 20: 259 – 67.en_US
dc.identifier.citedreferenceLiu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48 – 53.en_US
dc.identifier.citedreferenceFoss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001; 182: 19S – 26S.en_US
dc.identifier.citedreferenceGonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784 – 91.en_US
dc.identifier.citedreferenceTalley NJ, Weaver AL, Zinmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584 – 9.en_US
dc.identifier.citedreferenceCutts TF, Abell TL, Karas JG, Kuns J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996; 41: 1369 – 78.en_US
dc.identifier.citedreferenceClouse RE, Lustman PJ. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol 1989; 84: 868 – 72.en_US
dc.identifier.citedreferenceDrossman DA, Talley NJ, Leserman J, Olden KW, Barriero MA. Sexual and physical abuse in gastrointestinal illness. Review and recommendations. Ann Intern Med 1995; 123: 782 – 94.en_US
dc.identifier.citedreferenceCutts TF, Luo J, Starkebaum W, Rashid H, Abell TL. Gastric electrical stimulation is superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term healthcare benefits. Neurogastroenterol Motil 2005; 17: 35 – 43.en_US
dc.identifier.citedreferenceWagner EH, Glasgow RE, Davis C et al. Quality improvement in chronic illness care: a collaborative approach. J Jt Comm Health Care Qual 2001; 27: 63 – 80.en_US
dc.identifier.citedreferenceRashed H, Cutts T, Luo J et al. Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig Dis Sci 2002; 47: 1020 – 6.en_US
dc.identifier.citedreferenceHorowitz M, Edelbroek M, Fraser R, Maddox A, Wishart J. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol 1991; 26: 673 – 84.en_US
dc.identifier.citedreferenceBytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med 2001; 161: 1989 – 96.en_US
dc.identifier.citedreferenceMaleki D, Locke GR III, Camilleri M et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160: 2808 – 16.en_US
dc.identifier.citedreferenceZiegler D, Schadewaldt P, Pour Mirza A et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996; 39: 823 – 30.en_US
dc.identifier.citedreferenceTalley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003; 98: 274 – 1.en_US
dc.identifier.citedreferenceFraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 675 – 80.en_US
dc.identifier.citedreferenceOster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced hyperglycaemia on gastric emptying rate in healthy humans. Scand J Clin Lab Invest 1990; 50: 831 – 6.en_US
dc.identifier.citedreferenceJebbink RJ, Samsom M, Bruijs PP et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994; 107: 1390 – 7.en_US
dc.identifier.citedreferenceFrank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109: 755 – 65.en_US
dc.identifier.citedreferenceBarnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94: 739 – 44.en_US
dc.identifier.citedreferenceHasler WL, Soudah HC, Kulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108: 727 – 36.en_US
dc.identifier.citedreferenceJones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997; 20: 1141 – 6.en_US
dc.identifier.citedreferencePetrakis IE, Chalkiadakis G, Vrachassotakis N, Sciacca V, Vassilakis SJ, Xynos E. Induced-hyperglycemia attenuates erythromycin-induced acceleration of hypertonic liquid-phase gastric emptying in type I diabetic patients. Dig Dis Sci 1999; 17: 241 – 7.en_US
dc.identifier.citedreferenceJones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999; 22: 339 – 44.en_US
dc.identifier.citedreferenceGentilcore D, O'Donovan D, Jones KL, Horowitz M. Nutrition therapy for diabetic gastroparesis. Curr Diab Rep 2003; 35: 418 – 26.en_US
dc.identifier.citedreferenceLehmann R, Honegger RA, Feinle C, Freid M, Spinas GA, Schwizer W. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes and gastroparesis, a pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003; 111: 255 – 61.en_US
dc.identifier.citedreferenceRiddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080 – 6.en_US
dc.identifier.citedreferenceShopbell JM, Hopkins B, Shronts EP. Nutrition screening and assessment. In: Gottschlich M, ed. The Science and Practice of Nutrition Support: A Case-based Core Curriculum. Dubuque: Kendall/Hunt, 2001: 119 – 130.en_US
dc.identifier.citedreferenceParrish CR, Krenitsky J, McCray S. University of Virginia Health System Nutrition Support Traineeship Syllabus. 2003. Available at: http://www.healthsystem.virginia.edu/internet/dietitian/dh/traineeship.cfm (accessed 25 January 2006).en_US
dc.identifier.citedreferenceMcCray S, Walker S, Parrish CR. Much ado about refeeding. Pract Gastroenterol 2005; 29: 26 – 8.en_US
dc.identifier.citedreferenceGupta P, Rao SS. Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endosc 2002; 56: 770 – 2.en_US
dc.identifier.citedreferenceLacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection into the pylorus. Diabetes Care 2004; 27: 2341 – 7.en_US
dc.identifier.citedreferenceLacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002; 97: 1548 – 52.en_US
dc.identifier.citedreferenceMiller LS, Szych GA, Kantor SB et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002; 97: 1653 – 60.en_US
dc.identifier.citedreferenceEzzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002; 55: 920 – 3.en_US
dc.identifier.citedreferenceArts J, Van Gool S, Caenepeel P, Janssens J, Tack J. Effect of intrapyloric injection of botulinum toxin on gastric emptying and meal-related symptoms in gastroparesis. Gastroenterology 2003; 124: A53 (abstract).en_US
dc.identifier.citedreferenceBromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for treatment of refractory gastroparesis. Gastrointest Endosc 2005; 61: 833 – 9.en_US
dc.identifier.citedreferenceColeski R, Hasler W. Clinical and gastric functional predictors of symptom response to pyloric injection of botulinum toxin in patients with gastroparesis. Neurogastroenterol Motil 2005; 17: 628 (abstract).en_US
dc.identifier.citedreferenceArts J, Caenepeel P, Degreef T et al. Randomized double-blind cross-over study evaluation the effect of intrapyloric injection of botulinum toxin on gastric emptying and symptoms in patients with gastroparesis. Gastroenterology 2005; 128: A81 (abstract).en_US
dc.identifier.citedreferenceKim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998; 47: 67 – 70.en_US
dc.identifier.citedreferenceJones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003; 98: 2122 – 9.en_US
dc.identifier.citedreferenceMcCallum RW, Chen JDZ, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114: 456 – 61.en_US
dc.identifier.citedreferenceAbell T, Custem EV, Abrahamsson H. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002; 66: 204 – 21.en_US
dc.identifier.citedreferenceAbell T, McCallum R, Hocking M et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003; 125: 421 – 8.en_US
dc.identifier.citedreferenceAbell T, Lou J, Tabaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow up. J Parenter Enteral Nutr 2003; 98: 277 – 81.en_US
dc.identifier.citedreferenceLin Z, Forster J, Sarosiek I, McCallum RW. Treatment of gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care 2004; 27: 1071 – 6.en_US
dc.identifier.citedreferenceLin Z, McElhinney C, Sarosiek I, Forster J, McCallum R. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci 2005; 50: 1328 – 34.en_US
dc.identifier.citedreferenceAbell T, Al-Juburi A, Bashed H, Mirocha A. 13 years, 214 patients and over 5000 patient months: a long term report on gastric electric stimulation. Gastroenterology 2005; 128 ( 4 Suppl. 2 ): A282 (abstract).en_US
dc.identifier.citedreferenceOubre B, Luo J, Al-Juburi A, Voeller G, Familoni B, Abell TL. Pilot study on gastric electric stimulation on surgery-associated gastroparesis: long-term outcome. South Med J 2005; 98: 693 – 7.en_US
dc.identifier.citedreferenceMcCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005; 3: 49 – 54.en_US
dc.identifier.citedreferenceAyinala S, Batista O, Goyal A et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc 2005; 61: 455 – 61.en_US
dc.identifier.citedreferenceLin Z, Cocjin J, Sarosiek I, Roeser K, McCallum RW. Influence of high-frequency electrical stimulation on gastric electrical activity, autonomic function and symptoms in gastroparetic patients. Neurogastroenterol Motil 2005; 17: 480 – 1.en_US
dc.identifier.citedreferenceTack J, Coulie B, Van Custem E et al. The influence of gastric electrical stimulation on proximal gastric motor and sensory function in severe idiopathic gastroparesis. Gastroenterology 1999; 116: G4733 (abstract).en_US
dc.identifier.citedreferenceCocjin J, Lin Z, Scoggan R, Sarosiek I, McCallum RW. Effects of high-frequency low-energy gastric electrical stimulation (Enterra device) on gastric distention and tone in gastroparetic patients. Gastroenterology 2005; 128: A136 (abstract).en_US
dc.identifier.citedreferenceMcCallum RW, Dusing R, McMillin C et al. Fluoro-deoxyglucose (FDG) positron emission tomography (PET) in gastroparetic patients before and during gastric electrical stimulation (GES). Gastroenterolgy 2005; 128: A622 (abstract).en_US
dc.identifier.citedreferenceHasler W. Nonoperative management of patients with gastroparesis referred for gastric electrical stimulator implantation. Neurogastroenterol Motil 2005; 17: 480 (abstract).en_US
dc.identifier.citedreferenceSkole KS, Panganamamula KV, Bromer MQ, Meilahn JE, Fisher RS, Parkman HP. Efficacy of gastric electric stimulation for gastroparesis refractory to medical therapy. Am J Gastroenterol 2002; 97: S48 (abstract).en_US
dc.identifier.citedreferenceWatkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet Med 2003; 20: 58 – 63.en_US
dc.identifier.citedreferenceKarlstrom L, Kelly KA. Roux-Y gastrectomy for chronic gastric atony. Am J Surg 1989; 157: 44 – 9.en_US
dc.identifier.citedreferenceMcCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Dig Dis Sci 1991; 36: 1556 – 61.en_US
dc.identifier.citedreferenceEckhauser RE, Conrad M, Knol JA, Mulholland MW, Colletti LM. Safety and long-term durability of completion gastrectomy in 81 patients with postsurgical gastroparesis syndrome. Am Surg 1998; 64: 711 – 7.en_US
dc.identifier.citedreferenceForstner-Barthell AW, Murr MM, Nitecki S et al. Near-total completion gastrectomy for severe postvagotomy gastric stasis. J Gastrointest Surg 1999; 3: 15 – 21.en_US
dc.identifier.citedreferenceKennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 1031 – 7.en_US
dc.identifier.citedreferenceMurat A, Pouliquen B, Cantarovich D et al. Gastric emptying improvement after simultaneous segmental pancreas and kidney transplantation. Transplant Proc 1992; 24: 855.en_US
dc.identifier.citedreferenceHathaway DK, Abell T, Cardoso S, Hartwig MS, el Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 1994; 57: 816 – 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2982.2006.00760.x.pdf
Size:
174.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.